Omega Therapeutics (OMGA)
(Delayed Data from NSDQ)
$1.09 USD
-0.11 (-9.17%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $1.10 +0.01 (0.92%) 5:22 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.09 USD
-0.11 (-9.17%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $1.10 +0.01 (0.92%) 5:22 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Zacks News
Omega Therapeutics, Inc. (OMGA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Omega Therapeutics (OMGA) delivered earnings and revenue surprises of 16.67% and 71.27%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Nurix Therapeutics (NRIX) Surges 20.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Omega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Omega Therapeutics (OMGA) delivered earnings and revenue surprises of 5.26% and 155.14%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings?
by Zacks Equity Research
Novo Nordisk's (NVO) revenues in the first quarter of 2024 are expected to have been driven by its diabetes and obesity care product sales, especially Ozempic, Rybelsus and Wegovy.
Omega Therapeutics, Inc. (OMGA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Omega Therapeutics (OMGA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
by Zacks Equity Research
Investors are likely to focus on Opdivo's demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) posts Q1 results.
Omega Therapeutics (OMGA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Omega Therapeutics (OMGA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Omega Therapeutics (OMGA) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Omega Therapeutics (OMGA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Omega Therapeutics, Inc. (OMGA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Omega Therapeutics (OMGA) delivered earnings and revenue surprises of 19.57% and 6.92%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Sutro Biopharma (STRO) delivered earnings and revenue surprises of 151.22% and 834.90%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Omega (OMGA) Up 95% on Obesity Drug Deal With Novo Nordisk
by Zacks Equity Research
Using Omega's (OMGA) proprietary technology platform, Novo Nordisk (NVO) intends to develop a novel therapeutic for obesity, which will enhance the body's metabolism activity to burn excess fats.
Novo Nordisk (NVO) Up on $1.1B Research Deals With 2 Biotechs
by Zacks Equity Research
Novo Nordisk (NVO) gains 4% after signing $1.1 billion research collaboration agreements with two biotech companies to develop novel treatment approaches for cardiometabolic diseases.
Omega Therapeutics, Inc. (OMGA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Omega Therapeutics, Inc. (OMGA) delivered earnings and revenue surprises of -5.88% and 21.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Mirati (MRTX) Down 7% on CHMP's Opinion on Krazati Filing
by Zacks Equity Research
Per the CHMP, Mirati's (MRTX) regulatory filing for Krazati in KRASG12C mutated NSCLC does not fulfill certain requirements to support a conditional marketing authorization.
J&J (JNJ) Q2 Earnings & Sales Top, '23 View Upped, Stock Jumps
by Zacks Equity Research
J&J (JNJ) beats estimates for second-quarter earnings and sales. It raises full-year sales and earnings guidance.
Merck (MRK) Keytruda Advanced Cervical Cancer Study Meets Goal
by Zacks Equity Research
Interim data from a late-stage study, evaluating Merck's (MRK) Keytruda as a combination therapy, met one of its primary endpoints of progression-free survival.
Recursion (RXRX) Stock Surges 191% in 3 Months: Here's Why
by Zacks Equity Research
Recursion's (RXRX) shares rallied almost 191% over the past three months, owing to artificial intelligence-driven acquisitions and strategic collaborations to advance drug development.
Amarin (AMRN) Dips 16% on Layoff Plan & Preliminary Sales Miss
by Zacks Equity Research
Amarin (AMRN) decides to initiate a restructuring plan to maximize cash flow opportunities in the United States. It also reports preliminary product revenues of around $65 million in Q2.
Pieris (PIRS) Pursues Strategic Alternatives, Stock Rises
by Zacks Equity Research
Pieris (PIRS) announces strategic update after partner AstraZeneca terminated collaboration agreement and returned the rights to elarekibep.
BridgeBio (BBIO) Up as Heart Drug Meets Primary Goal in Study
by Zacks Equity Research
BridgeBio's (BBIO) shares surge on announcing positive data from a late-stage study evaluating acoramidis for patients with transthyretin amyloid cardiomyopathy.
Corcept's (CORT) Early-Stage Study on NASH Reveals Positive Data
by Zacks Equity Research
Corcept's (CORT) early-stage candidate miricorilant, evaluated to treat patients with presumed non-alcoholic steatohepatitis, shows encouraging data.
Apellis (APLS) Stock Surges 62% in 6 Months: Here's Why
by Zacks Equity Research
Apellis' (APLS) shares have rallied 62% over the past six months due to the approval of Syfovre (pegcetacoplan injection) in February. An encouraging uptake of its first marketed product, Empaveli, has further bolstered the stock value.
Recursion (RXRX) Up on $50M NVDA Investment for AI Drug Discovery
by Zacks Equity Research
Recursion (RXRX) soars on receiving an investment worth $50 million from Nivida for drug development using artificial intelligence.
Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301
by Zacks Equity Research
Aridis (ARDS) achieves a milestone as the FDA granted the Qualified Infectious Disease Product designation for AR-301.